Analyst consensus rating
Corbus Pharmaceuticals Holdings Analyst Rating: Strong Buy
Direct answer
Corbus Pharmaceuticals Holdings's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $34.03.
Forecast evidence checked September 5, 2026.
Get free Corbus Pharmaceuticals Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.08
- Average price target
- $34.03
- High price target
- $48.00
- Low price target
- $17.25
- Low target gap
- +55.7%
- Target upside
- +207.1%
- High target gap
- +333.2%
- Target range width
- 277.5%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Corbus Pharmaceuticals Holdings?
Corbus Pharmaceuticals Holdings has a verified Strong Buy consensus. The same dataset has an average price target of $34.03.
How far are Corbus Pharmaceuticals Holdings's low and high targets from the recorded price?
The low target implies +55.7%, while the high target implies +333.2%.
How many analysts are included in Corbus Pharmaceuticals Holdings's consensus?
The verified consensus includes 10 analysts.
How is Corbus Pharmaceuticals Holdings's target upside or downside calculated?
The average target of $34.03 is divided by the recorded price of $11.08, then one is subtracted to produce +207.1%. This does not guarantee a future return.
When was Corbus Pharmaceuticals Holdings's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.